Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 20/20 | 0.72 |
| ▸ | MAPK12 | P53778 | 17/20 | 0.72 |
| ▸ | HCK | P08631 | 16/20 | 0.72 |
| ▸ | SRC | P12931 | 2/20 | 0.72 |
| ▸ | TNF | P01375 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17017208 | 0.96 | MAPK14 (0.70) | MAPK14MAPK12HCKSRCTNF | |
| SCHEMBL17017200 | 0.94 | MAPK14 (0.75) | MAPK14MAPK12HCKSRCTNF | |
| SCHEMBL17017716 | 0.94 | MAPK14 (0.73) | MAPK14MAPK12HCKSRCTNF | |
| SCHEMBL17004778 | 0.94 | MAPK14 (0.76) | MAPK14MAPK12HCKSRCTNF | |
| SCHEMBL17017177 | 0.93 | MAPK14 (0.71) | MAPK14MAPK12HCKSRCTNF | |
| SCHEMBL18546344 | 0.92 | MAPK14 (0.74) | MAPK14MAPK12HCKSRCTNF | |
| SCHEMBL17017989 | 0.92 | MAPK14 (0.71) | MAPK14MAPK12HCKSRCTNF | |
| SCHEMBL17017810 | 0.91 | MAPK14 (0.72) | MAPK14MAPK12HCKSRCTNF | |
| SCHEMBL17017999 | 0.91 | MAPK14 (0.68) | MAPK14MAPK12HCKSRCTNF | |
| SCHEMBL17017654 | 0.91 | MAPK14 (0.75) | MAPK14MAPK12HCKSRCTNF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106573914-B | Pyrazolyl-ureas as kinase inhibitors | 瑞斯比维特有限公司 | 2021-05-28 | — | — | CN | claimed |
| EP-3105223-B1 | PYRAZOLYL-UREAS AS KINASE INHIBITORS | RESPIVERT LTD (GB) | 2018-09-12 | — | — | EP | claimed |
| US-9884845-B2 | Pyrazolyl-ureas as kinase inhibitors | RESPIVERT LIMITED (GB) | 2018-02-06 | — | — | US | claimed |
| US-11142515-B2 | Pyrazolyl-ureas as kinase inhibitors | RESPIVERT LIMITED (GB) | 2021-10-12 | — | — | US | disclosed |
| US-11142515-B2 | Pyrazolyl-ureas as kinase inhibitors | RESPIVERT LIMITED (GB) | 2021-10-12 | — | — | US | disclosed |
| CN-113264921-A | Pyrazolyl-ureas as kinase inhibitors | 瑞斯比维特有限公司 | 2021-08-17 | — | — | CN | disclosed |
| EP-3418279-B1 | DRY POWDER PHARMACEUTICAL FORMULATION | RESPIVERT LTD (GB) | 2021-01-20 | — | — | EP | disclosed |
| EP-3418279-B1 | DRY POWDER PHARMACEUTICAL FORMULATION | RESPIVERT LTD (GB) | 2021-01-20 | — | — | EP | disclosed |
| US-10294216-B2 | Pyrazolyl ureas as kinase inhibitors | RESPIVERT LIMITED (GB) | 2019-05-21 | — | — | US | disclosed |
| US-10294216-B2 | Pyrazolyl ureas as kinase inhibitors | RESPIVERT LIMITED (GB) | 2019-05-21 | — | — | US | disclosed |
| EP-3418279-A1 | AROMATIC HETEROCYCLIC COMPOUNDS AS ANTIINFLAMMATORY COMPOUNDS | Respivert Limited (GB) | 2018-12-26 | — | — | EP | disclosed |
| US-20180118719-A1 | PYRAZOLYL UREAS AS KINASE INHIBITORS | RESPIVERT LIMITED (GB) | 2018-05-03 | — | — | US | disclosed |
| US-20180118719-A1 | PYRAZOLYL UREAS AS KINASE INHIBITORS | RESPIVERT LIMITED (GB) | 2018-05-03 | — | — | US | disclosed |
| US-20180118719-A1 | PYRAZOLYL UREAS AS KINASE INHIBITORS | RESPIVERT LIMITED (GB) | 2018-05-03 | — | — | US | disclosed |
| US-9884845-B2 | Pyrazolyl-ureas as kinase inhibitors | RESPIVERT LIMITED (GB) | 2018-02-06 | — | — | US | disclosed |
| US-9884845-B2 | Pyrazolyl-ureas as kinase inhibitors | RESPIVERT LIMITED (GB) | 2018-02-06 | — | — | US | disclosed |
| US-9884845-B2 | Pyrazolyl-ureas as kinase inhibitors | RESPIVERT LIMITED (GB) | 2018-02-06 | — | — | US | disclosed |
| US-20170057945-A1 | NOVEL COMPOUNDS | RESPIVERT LIMITED (GB) | 2017-03-02 | — | — | US | disclosed |
| US-20170057945-A1 | NOVEL COMPOUNDS | RESPIVERT LIMITED (GB) | 2017-03-02 | — | — | US | disclosed |
| WO-2015121660-A1 | PYRAZOLYL-UREAS AS KINASE INHIBITORS | RESPIVERT LIMITED (GB) | 2015-08-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10294216-B2 | Pyrazolyl ureas as kinase inhibitors | MAP3K1, MAP3K2, MAP3K8 | MAPK14 18/4885MAPK12 43/4885HCK 773/4885 |
| US-20180118719-A1 | PYRAZOLYL UREAS AS KINASE INHIBITORS | MAP3K1, MAPK1, MAP3K7 | MAPK14 16/4885MAPK12 37/4885HCK 553/4885 |
| US-11142515-B2 | Pyrazolyl-ureas as kinase inhibitors | MAPK1, MAP3K1, MAP3K8 | MAPK14 12/4885MAPK12 37/4885HCK 730/4885 |
| US-20170057945-A1 | NOVEL COMPOUNDS | MAPK1, MAPK6, MAPKAPK2 | MAPK14 4/4885MAPK12 13/4885HCK 2965/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.